All In Biotech

Drug Trial Radar · NCT07079475

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • DZD6008Drug

    DZD6008 will be administered orally at 40/60 mg QD or selected dose.

  • SunvozertinibDrug

    Sunvozertinib will be administered orally at 100/200 mg QD or selected dose.

  • OsimertinibDrug

    Osimertinib will be administered orally at 80 mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To assess safety and tolerabilityTime frame: Through the study completion, an average of around 2 years
  2. Part A: To assess safety and tolerabilityTime frame: 21 days after the first dose
  3. Part B: To assess anti-tumor activityTime frame: Through the study completion, an average of around 2 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Jiangsu People's Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Nanjing Gulou Hospital

    Nanjing, Jiangsu, China · Recruiting

  • First Affilicated Hospital of China Medical University

    Shengyang, Liaoning, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Taizhou Hospital

    Taizhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.